RT Journal Article
SR Electronic
T1 Novel ELISA protocol links pre-existing SARS-CoV-2 reactive antibodies with endemic coronavirus immunity and age and reveals improved serologic identification of acute COVID-19 via multi-parameter detection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.15.20192765
DO 10.1101/2020.09.15.20192765
A1 Yuen, Rachel R.
A1 Steiner, Dylan
A1 Smith, Erika L.
A1 Pihl, Riley M.F.
A1 Chavez, Elizabeth
A1 Olson, Alex
A1 Baird, Lillia A.
A1 Korkmaz, Filiz
A1 Urick, Patricia
A1 Sagar, Manish
A1 Berrigan, Jacob L.
A1 Gummuluru, Suryaram
A1 Corley, Ronald B.
A1 Quillen, Karen
A1 Belkina, Anna C.
A1 Mostoslavsky, Gustavo
A1 Gao, Wenda
A1 Rifkin, Ian
A1 Cappione, Amedeo J.
A1 Lin, Nina H.
A1 Kataria, Yachana
A1 Bhadelia, Nahid
A1 Snyder-Cappione, Jennifer E.
YR 2020
UL http://medrxiv.org/content/early/2020/12/23/2020.09.15.20192765.abstract
AB The COVID-19 pandemic has drastically impacted work, economy, and way of life worldwide in 2020. Sensitive measurement of SARS-CoV-2 specific antibodies would provide new insight into pre-existing immunity, virus transmission dynamics, and the nuances of SARS-CoV-2 pathogenesis. To date, existing SARS-CoV-2 serology tests have limited utility due to insufficient reliable detection of antibody levels lower than what is typically present after several days of symptoms. To measure lower quantities of SARS-CoV-2 IgM, IgG, and IgA with higher resolution than existing assays, we developed a new ELISA protocol with a distinct plate washing procedure and timed plate development via use of a standard curve. This ‘BU ELISA’ method exhibits very low signal from samples added to buffer coated wells at as low as a 1:5 dilution. Use of this method revealed circulating SARS-CoV-2 receptor binding domain (RBD) and nucleocapsid protein (N) reactive antibodies (IgG, IgM, and/or IgA) in 44 and 100 percent of pre-pandemic subjects, respectively, and the magnitude of these antibodies tracked with antibody levels of analogous viral proteins from the 229E and/or NL63 endemic coronavirus (eCoV) strains. The disease status (HIV, SLE) of unexposed subjects was not linked with SARS-CoV-2 reactive antibody levels; however, quantities were significantly lower in subjects over 70 years of age compared with younger counterparts. Also, we measured SARS-CoV-2 RBD- and N-specific IgM, IgG, and IgA antibodies from 29 SARS-CoV-2 infected individuals at varying disease states, including 10 acute COVID-19 hospitalized subjects with negative serology results by the EUA approved Abbott IgG chemiluminescent microparticle immunoassay. Measurements of SARS-CoV-2 RBD- and N-specific IgM, IgG, IgA levels measured by the BU ELISA revealed higher signal from 9 of the 10 Abbott test negative COVID-19 subjects than all pre-pandemic samples for at least one antibody specificity/isotype, implicating improved serologic identification of SARS-CoV-2 infection via multi-parameter, high sensitive antibody detection. We propose that this improved ELISA protocol, which is straightforward to perform, low cost, and uses readily available commercial reagents, is a useful tool to elucidate new information about SARS-CoV-2 infection and immunity and has promising implications for improved detection of all analytes measurable by this platform.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Boston University National Emerging Infectious Diseases Laboratories Director Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of all samples was approved by the Boston University Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.